cellceutix is an emerging bio-pharmaceutical company
focusing in the areas of cancer
and inflammatory disease...
Press Release 11/7/2011

Cellceutix Files Investigational New Drug Application (IND) with FDA, Clinical Trials Planned at Dana-Farber/Harvard Cancer Center
 
 
Cellceutix at AACR
Cellceutix will be presenting an abstract entitled : "Novel small molecule has potent antitumor activity in drug-resistant human carcinoma xenograft models" at a poster session on April 20. Further details are provided below:  

Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2 
Session Date and Time: Tuesday Apr 20, 2010 2:00 PM - 5:00 PM 
Location: Exhibit Hall A-C, Poster Section 39 
Permanent Abstract Number: LB-283
 
 
Cellceutix Featured on Cover of Prominent Business Journal
Cellceutix Ushers in 2012 With Plans for Clinical Trials for Anti-Cancer and Psoriasis Drugs
Cellceutix Provides Updates on IND for Cancer Drug - Initiates Collaborative Agreement With Pioneer
Dr Paul Marks MD Joins Cellceutix Scientific Advisory Board; Cellceutix Files Worldwide Patents
Cellceutix Files Investigational New Drug Application (IND) with FDA
Cellceutix to File Investigational New Drug Application for Novel p53 Anti-Cancer Drug
Cellceutix Confident as Cancer Compound Shows Activity in All Cancers Tested
Prostate Cancer Joins Growing List of Cancers That Succumb to Kevetrin
Cellceutix's Drug Discovery Is a Major Leap Forward in the Fight Against Cancer
Cellceutix to Pursue 505(b)(2) Clinical Process for Psoriasis Drug
Cellceutix Signs Lab Services Research Support Agreement With Dana Farber-Partners CancerCare Inc.
With Contracts and IND Application in Hand, Cellceutix Nears Clinical Trials for New Cancer Drug
Cellceutix Receives Notice of Acceptance for Phase 1 Clinical Trial
Cellceutix Provides Updates on Kevetrin - Cellceutixs Novel Anti-Cancer Therapy
Cellceutixs KevetrinSlows Pancreatic Cancer Tumor Growth by 94 percent - Protocol Towards Clinical
Vendor Showcases Kevetrin (TM)- Anti-Cancer Drug at American Society for Mass Spectromet
Cellceutix CEO States - Full Speed Ahead
Kevetrin in Combination with Radiation Delayed Tumor Growth by Twofold in Head and Neck Cancer Study
Cellceutix Forwards Cancer Drug Study Protocol to Clinical Site
Insight Into Cellceutix Corporation's Breakthrough Cancer Compound
Cellceutix Cancer Drug Trumps Competitors
Interview w Biotech Stock Trader- Dr. Paul Ginsberg Joins Cellceutix Advisory Board
Cellceutix Poster Presentation on its p53 Cancer Breakthrough Attracts Wide Interest at 102nd AACR M
Cellceutix Cancer Drug, Kevetrin, Shows Increased Levels of p21; Biomarker for Cancer Trials
Cellceutix Announces that it has Signed Confidential Disclosure Agreement for its Autism Drug with L
Cellceutix Anti-Cancer Breakthrough Selected for Poster Presentation at AACR
Cellceutix Reports Production of Its Anti-Cancer Drug Kevetrin Has Begun
Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company
Cellceutix Discovers Drug Activates - Guardian Angel p53 - in Fight Against Leukemia
Cellceutix Cancer Drug Kevetrin Shows No Genotoxicity in Study
Cellceutix Makes Breakthrough in Cancer Research by Activating p53, the Guardian Angel of the Human
Cellceutix Announces Settlement With Former CEO
Cellceutix Announces Departure of George W. Evans as CEO
Cellceutix Receives Federal Grants for Each of Its Active Research Programs - Total Exceeds $730K
Nearing Completion of Toxicity Studies for Its Cancer Compound for Resistant Lung and Breast Cancers
Cellceutix Nearing Completion of Toxicity Studies for Its Cancer Compound for the Treatment
Cellceutix Closing in on Human Trials with Kevetrin for Drug-Resistant Cancers
Cellceutix Corporation Selects Destum Partners to Partner Psoriasis Compound
Cellceutix Completes All Three Animal Safety Pharmacology Studies for Its Cancer Compound Req by FDA
Cellceutix Autism Research Demonstrates Increase in Serotonin Levels in Three Areas of the Brain
Kevetrin Demonstrates Significant Results in the Treatment of Multi-Drug Resistant Cancer Cells
New Autism Drug Research by Cellceutix on Compound KM-391 Results in Significant Behavioral Changes
Cellceutix Responds to Public Support by Expediting Autism Studies - Completes Two Required Safety P
Cellceutix CFO Discusses Autism Drug - Kevetrin and Company Progressions with CEOCFO Interviews and
Cellceutix Signs Agreements for Kevetrin(TM) Phase 1 Support; Company Continues to Advance Kevetrin
Cellceutix Files Foreign Patent Application in PCT and Other Key Countries for Its Flagship Cancer C
Recent Announcements Suggest Cellceutix Is Well Positioned With Autism Compound Pfizer and Novartis
Cellceutix Presents Poster Session at AACR Important New Data on Kevetrin in Resistant Lung Can
Cellceutix at AACR
Cellceutix Ceo Appears On Stu Taylor On Business - Cancer And Autism Compounds Are Discussed
Cellceutix Announces Positive Results With Autism Compound
Cellceutix Signs Agreement for Kevetrin(TM) Formulation With Formatech
Cellceutix Abstract Accepted by AACR
Cellceutix Completes Successful Pre-IND Meeting With FDA for Cancer Drug
Cellceutix Signs Agreement for Kevetrin(TM) Safety Studies with Toxikon Corporation
Cellceutix Poster Presented at American Association for Cancer Research
Cellceutix Compound Shows Significant Effect On Psoriasis
Kevetrin" Demonstrates Significant Delay of Tumor Growth in Drug Resistant Breast Cancer
Cellceutix Announces Acquisition of New Compound With High Blood Pressure Lowering Properties
Cellceutix Signs Manufacturing Agreement for Kevetrin Active Pharmaceutical Ingredient
Cellceutix Announces Dr. Samuel Danishefsky Joins Its Scientific Advisory Board
CTIX Announces Lung Cancer Animal Model Testing Results with Kevetrin
Cellceutix Announces Dr. Emil Frei to be On Its Scientific Advisory Board Through June 30, 2010
Cellceutix cancer compound: Crunching the numbers